Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease

Neurobiology of Aging

Volumn 35, Issue 5, 2014, Pages 1111-1115

  Dunn, Laura ^a   Allen, George FG ^b   Mamais, Adamantios ^a   Ling, Helen ^a,c   Li, Abi ^c   Duberley, Kate E ^c,f   Hargreaves, Iain P ^f   Pope, Simon ^f   Holton, Janice L ^c   Lees, Andrew ^a   Heales, Simon J ^c,d,e   Bandopadhyay, Rina ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Glucose metabolism; NADPH; Neurodegeneration; Parkinson's disease; Pentose phosphate pathway

Indexed keywords

GLUCOSE METABOLISM; NADPH; NEURODEGENERATION; PARKINSON'S DISEASE; PENTOSE-PHOSPHATE PATHWAY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIOXIDANTS; CELL DEATH; CEREBELLUM; DOPAMINERGIC NEURONS; FEMALE; GLUCOSE; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; MALE; NADP; NEURONS; PARKINSON DISEASE; PENTOSE PHOSPHATE PATHWAY; PHOSPHOGLUCONATE DEHYDROGENASE; PUTAMEN;

EID: 84893715802     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.11.001     Document Type: Article

References (38)

1. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J.Neurochem. 1997, 69:1196-1203.
2. Ben-Yoseph O., Boxer P.A., Ross B.D. Oxidative stress in the central nervous system: monitoring the metabolic response using the pentose phosphate pathway. Dev. Neurosci. 1994, 16:328-336.
3. Bolanos J.P., Heales S.J. Persistent mitochondrial damage by nitric oxide and its derivatives: neuropathological implications. Front Neuroenergetics 2010, 2.
4. Borghammer P. Perfusion and metabolism imaging studies in Parkinson's disease. Dan. Med. J. 2012, 59:B4466.
5. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
6. Cosentino C., Grieco D., Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J. 2011, 30:546-555.
7. Dalfo E., Portero-Otin M., Ayala V., Martinez A., Pamplona R., Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J.Neuropathol. Exp. Neurol. 2005, 64:816-830.
8. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J.Neurochem. 1989, 52:381-389.
9. Ferrer I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog. Neurobiol. 2009, 88:89-103.
10. Filosa S., Fico A., Paglialunga F., Balestrieri M., Crooke A., Verde P., Abrescia P., Bautista J.M., Martini G. Failure to increase glucose consumption through the pentose-phosphate pathway results in the death of glucose-6-phosphate dehydrogenase gene-deleted mouse embryonic stem cells subjected to oxidative stress. Biochem. J. 2003, 370:935-943.
11. Floor E., Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J.Neurochem. 1998, 70:268-275.
12. Gupte S.A. Glucose-6-phosphate dehydrogenase: a novel therapeutic target in cardiovascular diseases. Curr. Opin. Investig. Drugs 2008, 9:993-1000.
13. Harkavyi A., Abuirmeileh A., Lever R., Kingsbury A.E., Biggs C.S., Whitton P.S. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J.Neuroinflammation 2008, 5.
14. Heales S.J., Davies S.E., Bates T.E., Clark J.B. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem. Res. 1995, 20:31-38.
15. Herken H. Neurotoxin-induced impairment of biopterin synthesis and function: Initial stage of a Parkinson-like dopamine deficiency syndrome. Neurochem. Int. 1990, 17:223-238.
16. Herrero-Mendez A., Almeida A., Fernandez E., Maestre C., Moncada S., Bolanos J.P. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell Biol. 2009, 11:747-752.
17. Ikawa M., Okazawa H., Kudo T., Kuriyama M., Fujibayashi Y., Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl. Med. Biol. 2011, 38:945-951.
18. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526.
19. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47:S161-170.
20. Kirby J., Halligan E., Baptista M.J., Allen S., Heath P.R., Holden H., Barber S.C., Loynes C.A., Wood-Allum C.A., Lunec J., Shaw P.J. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 2005, 128:1686-1706.
21. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A 2009, 106:1285-1290.
22. Martins R.N., Harper C.G., Stokes G.B., Masters C.L. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J.Neurochem. 1986, 46:1042-1045.
23. Marttila R.J., Lorentz H., Rinne U.K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J.Neurol. Sci. 1988, 86:321-331.
24. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
25. Meijer A.E. The pentose phosphate pathway in skeletal muscle under patho-physiological conditions. A combined histochemical and biochemical study. Prog. Histochem. Cytochem. 1991, 22:1-118.
26. Ninfali P., Aluigi G., Balduini W., Pompella A. Glucose-6-phosphate dehydrogenase activity is higher in the olfactory bulb than in other brain areas. Brain Res. 1997, 744:138-142.
27. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57:168-175.
28. Pandolfi P.P., Sonati F., Rivi R., Mason P., Grosveld F., Luzzatto L. Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. EMBO J. 1995, 14:5209-5215.
29. Parker W.D., Parks J.K., Swerdlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 2008, 1189:215-218.
30. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 1982, 33:305-310.
31. Rodriguez-Araujo G., Nakagami H., Hayashi H., Mori M., Shiuchi T., Minokoshi Y., Nakaoka Y., Takami Y., Komuro I., Morishita R., Kaneda Y. Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway. Cell Mol. Life Sci. 2013, 70:1123-1133.
32. Salvemini F., Franze A., Iervolino A., Filosa S., Salzano S., Ursini M.V. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J.Biol. Chem. 1999, 274:2750-2757.
33. Sanchez-Ramos J., Overik E., Ames B. Amarker of oxyradical-mediated DNA damage (8-hydroxy-2'deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994, 3:197-204.
34. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
35. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36:348-355.
36. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 1992, 142:128-130.
37. Ursini M.V., Parrella A., Rosa G., Salzano S., Martini G. Enhanced expression of glucose-6-phosphate dehydrogenase in human cells sustaining oxidative stress. Biochem. J. 1997, 323:801-806.
38. Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., Eklund A.C., Zhang-James Y., Kim P.D., Hauser M.A., Grunblatt E., Moran L.B., Mandel S.A., Riederer P., Miller R.M., Federoff H.J., Wullner U., Papapetropoulos S., Youdim M.B., Cantuti-Castelvetri I., Young A.B., Vance J.M., Davis R.L., Hedreen J.C., Adler C.H., Beach T.G., Graeber M.B., Middleton F.A., Rochet J.C., Scherzer C.R. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2010, 2:52ra73.